JPS5826817A - 製薬組成物 - Google Patents

製薬組成物

Info

Publication number
JPS5826817A
JPS5826817A JP57132286A JP13228682A JPS5826817A JP S5826817 A JPS5826817 A JP S5826817A JP 57132286 A JP57132286 A JP 57132286A JP 13228682 A JP13228682 A JP 13228682A JP S5826817 A JPS5826817 A JP S5826817A
Authority
JP
Japan
Prior art keywords
platelet
anabrelide
anagrelide
activity
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57132286A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0237328B2 (enExample
Inventor
ジエ−ムズ・スチユア−ト・フレミング・ジユニア
ジヨセフ・ポ−ル・ブイニスキ−
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of JPS5826817A publication Critical patent/JPS5826817A/ja
Publication of JPH0237328B2 publication Critical patent/JPH0237328B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP57132286A 1981-07-30 1982-07-30 製薬組成物 Granted JPS5826817A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/288,639 US4357330A (en) 1981-07-30 1981-07-30 Pharmaceutical compositions
US288639 1988-12-21

Publications (2)

Publication Number Publication Date
JPS5826817A true JPS5826817A (ja) 1983-02-17
JPH0237328B2 JPH0237328B2 (enExample) 1990-08-23

Family

ID=23107996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57132286A Granted JPS5826817A (ja) 1981-07-30 1982-07-30 製薬組成物

Country Status (12)

Country Link
US (1) US4357330A (enExample)
JP (1) JPS5826817A (enExample)
AU (1) AU559161B2 (enExample)
BE (1) BE893974A (enExample)
CA (1) CA1181010A (enExample)
DE (1) DE3228402A1 (enExample)
FR (1) FR2510406B1 (enExample)
GB (1) GB2103090B (enExample)
IE (1) IE54277B1 (enExample)
LU (1) LU84306A1 (enExample)
MY (1) MY8800110A (enExample)
ZA (1) ZA825397B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3524051A1 (de) * 1985-07-05 1987-01-15 Hoechst Ag Kombinationspraeparate aus hemmstoffen der thrombozytenaggregation und deren verwendung
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
EP0270316A3 (en) * 1986-12-04 1989-12-06 Pfizer Inc. Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne
AT393962B (de) * 1987-10-22 1992-01-10 Thomae Gmbh Dr K Synergistische arzneimittelkombination mit einem gehalt an einem phosphodiesterase-hemmer und derenverwendung
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
US6194420B1 (en) 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
AU2004206783B2 (en) * 2003-01-23 2009-03-26 Shire Holdings Ag Formulation and methods for the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
CN101463035A (zh) * 2007-12-19 2009-06-24 华生制药私人有限公司 生产盐酸阿那格雷一水合物的改进方法
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
GB201017783D0 (en) 2010-10-21 2010-12-01 Shire Llc Process for the preparation of anagrelide and analogues thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2307538A1 (fr) * 1975-04-18 1976-11-12 Centre Etd Ind Pharma Nouveau medicament anti-agregant plaquettaire
US4124715A (en) 1977-05-16 1978-11-07 Jose Pozuelo Method of pharmacologically treating drug addiction with fusaric acid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物

Also Published As

Publication number Publication date
FR2510406B1 (fr) 1986-05-09
CA1181010A (en) 1985-01-15
FR2510406A1 (fr) 1983-02-04
IE821828L (en) 1983-01-30
DE3228402C2 (enExample) 1992-01-23
AU559161B2 (en) 1987-02-26
US4357330A (en) 1982-11-02
MY8800110A (en) 1988-12-31
AU8652782A (en) 1983-02-03
IE54277B1 (en) 1989-08-16
BE893974A (fr) 1983-01-31
ZA825397B (en) 1983-06-29
DE3228402A1 (de) 1983-02-24
LU84306A1 (fr) 1983-04-13
GB2103090B (en) 1985-07-17
JPH0237328B2 (enExample) 1990-08-23
GB2103090A (en) 1983-02-16

Similar Documents

Publication Publication Date Title
JPS5826817A (ja) 製薬組成物
DE69636036T2 (de) Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten
US4132788A (en) Antiarthritic potentiation
EA008108B1 (ru) Комбинация нспвлс и ингибитора pde-4
US4444777A (en) Pharmaceutical compositions of anagrelide and sulfinpyrazone
CA2306985A1 (en) Novel use of compounds for anti-pruritic activity
HU193793B (en) Process for producing pharmaceutical compositions containing pyrimido-pyrimidines and o-acetyl-salicylic acid or pharmaceutically acceptable salts thereof
JP2009102399A (ja) 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法
EP1603573B1 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
US4432980A (en) Pharmaceutical compositions
Roy et al. Further studies on anti-inflammatory activity of two potent indan-1-acetic acids
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
PL206268B1 (pl) Kompozycja przeciwbólowa i/lub przeciwzapalna oraz jej zastosowanie
EP0006845B1 (en) Pharmaceutical composition comprising a 5-aroyl-1-c1-5 alkyl-pyrrole-2-acetic acid compound and acetaminophen or acetylsalicylic acid
US4933356A (en) Diflunisal potentiation of acetazolamide in the control of intraocular pressure
CZ283932B6 (cs) Použití mometason furoátu a salicylové kyseliny pro přípravu farmaceutického prostředku pro léčbu psoriasy a farmaceutický prostředek
Izzo et al. Recent acquisitions in pain therapy: meclofenamic acid
Miller et al. Zomepirac-induced renal failure
HRP20020362A2 (en) Use of 2-imidazolyl substituted carbinols for production of a medicament for treatment or prohylaxis of disease states as a result of ischaemic conditions
Lee et al. Uninephrectomy enhances urolithiasis in ethylene glycol treated rats
Hartshorn Drug Interactions Analgesics—Salicylates
EP0528076A1 (en) Use of Mebeverine against non-specific inflammatory bowel disease
Misraulia et al. Clinico-haematological changes after long term administration of NSAIDS.
Antihistamine Tetranicotinoylfructose. Peripheral
Van Dyke et al. Drugs Used in Gout